Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine

被引:104
作者
Williams, DP
Pirmohamed, M
Naisbitt, DJ
Uetrecht, JP
Park, BK
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England
[2] Univ Toronto, Fac Pharm, Toronto, ON, Canada
关键词
D O I
10.1124/mol.58.1.207
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Clozapine, an atypical antipsychotic used in the treatment of refractory schizophrenia, causes neutropenia and agranulocytosis in 3 and 0.8% of patients, respectively. Clozapine undergoes bioactivation to a chemically reactive nitrenium ion, which has been shown to cause neutrophil cytotoxicity. To define further the mechanism of cell death, we have investigated the toxicity of clozapine, its stable metabolites, and its chemically reactive nitrenium ion to neutrophils and lymphocytes. Clozapine was able to induce neutrophil apoptosis at therapeutic concentrations (1-3 mu M) only when it was bioactivated to the nitrenium ion. The parent drug caused apoptosis at supratherapeutic concentrations (100-300 mu M) only. Neutrophil apoptosis induced by the nitrenium ion, but not by the parent drug itself, was inhibited by antioxidants and genistein and was accompanied by cell surface haptenation (assessed by flow cytometry) and glutathione depletion. Dual-color flow cytometry showed that neutrophils that were haptenated were the same cells that underwent apoptosis. No apoptosis of lymphocytes was evident with the nitrenium ion or the parent drug, despite the fact that the former caused cell surface haptenation, glutathione depletion, and loss of membrane integrity. Demethylclozapine, the major stable metabolite in vivo, showed a profile that was similar to, although less marked than that observed with clozapine. N-oxidation of clozapine or replacement of the nitrogen (at position 5) by sulfur produced compounds that were entirely nontoxic to neutrophils. In conclusion, the findings of the study expand on potential mechanisms of clozapine-induced cytotoxicity, which may be of relevance to the major forms of toxicity encountered in patients taking this drug.
引用
收藏
页码:207 / 216
页数:10
相关论文
共 49 条
[11]  
EASTMOND DA, 1986, MOL PHARMACOL, V30, P674
[12]  
FISCHER V, 1991, MOL PHARMACOL, V40, P846
[13]  
Gardner I, 1998, MOL PHARMACOL, V53, P991
[14]  
Gardner I, 1998, MOL PHARMACOL, V53, P999
[15]  
GERSON SL, 1994, J CLIN PSYCHIAT, V55, P139
[16]   CLOZAPINE - DECIPHERING THE RISKS [J].
GERSON, SL .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) :204-205
[17]   Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis [J].
Guest, I ;
Sokoluk, B ;
MacCrimmon, J ;
Uetrecht, J .
TOXICOLOGY, 1998, 131 (01) :53-65
[18]   BCL2 PROTEIN IS TOPOGRAPHICALLY RESTRICTED IN TISSUES CHARACTERIZED BY APOPTOTIC CELL-DEATH [J].
HOCKENBERY, DM ;
ZUTTER, M ;
HICKEY, W ;
NAHM, M ;
KORSMEYER, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (16) :6961-6965
[19]   PHARMACOKINETICS AND PHARMACODYNAMICS OF CLOZAPINE [J].
JANN, MW ;
GRIMSLEY, SR ;
GRAY, EC ;
CHANG, WH .
CLINICAL PHARMACOKINETICS, 1993, 24 (02) :161-176
[20]   ANTIMYELOPEROXIDASE ANTIBODIES AND ADVERSE REACTIONS TO CLOZAPINE [J].
JAUNKALNS, R ;
SHEAR, NH ;
SOKOLUK, B ;
GARDNER, D ;
CLAAS, F ;
UETRECHT, JP .
LANCET, 1992, 339 (8809) :1611-1612